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Abstract
Background: Airway abnormalities and lung tissue citrullination are found in both rheumatoid arthritis (RA) patients
and individuals at-risk for disease development. This suggests the possibility that the lung could be a site of
autoimmunity generation in RA, perhaps in response to microbiota changes. We therefore sought to test whether
the RA lung microbiome contains distinct taxonomic features associated with local and/or systemic autoimmunity.
Methods: 16S rRNA gene high-throughput sequencing was utilized to compare the bacterial community
composition of bronchoalveolar lavage fluid (BAL) in patients with early, disease-modifying anti-rheumatic drugs
(DMARD)-naïve RA, patients with lung sarcoidosis, and healthy control subjects. Samples were further assessed for
the presence and levels of anti-citrullinated peptide antibodies (including fine specificities) in both BAL and serum.
Results: The BAL microbiota of RA patients was significantly less diverse and abundant when compared to healthy
controls, but similar to sarcoidosis patients. This distal airway dysbiosis was attributed to the reduced presence of
several genus (i.e., Actynomyces and Burkhordelia) as well as reported periodontopathic taxa, including Treponema,
Prevotella, and Porphyromonas. While multiple clades correlated with local and systemic levels of autoantibodies, the
genus Pseudonocardia and various related OTUs were the only taxa overrepresented in RA BAL and correlated with
higher disease activity and erosions.
Conclusions: Distal airway dysbiosis is present in untreated early RA and similar to that detected in sarcoidosis lung
inflammation. This community perturbation, which correlates with local and systemic autoimmune/inflammatory
changes, may potentially drive initiation of RA in a proportion of cases.
Background
Rheumatoid arthritis (RA) is currently considered a com-
plex, polygenic, and multifactorial disease. Novel concepts
in its etiopathogenesis posit that, in the right genetic back-
ground (i.e., “shared epitope” alleles), a proportion of these
individuals lose tolerance against self-peptides and enter a
prolonged autoimmune phase, characterized by the pro-
duction of circulating autoantibodies [(i.e., rheumatoid
factor (RF) and anti-citrullinated peptide antibodies
(ACPAs)] [1]. These antibodies, however, arise in the
circulation in the absence of major synovial pathology,
which has led to a renovated search for extra-articular
epigenetic and environmental triggers of disease [2].
Among the latter, interest in the role of microorganisms
residing in mucosal sites (i.e., microbiome) and the associ-
ated host immune response has reemerged [3]. Multiple
lines of investigation utilizing models of inflammatory
arthritis have demonstrated that, in the absence of bac-
teria, animals are typically spared from disease and that
perturbation in the bacterial community composition
(dysbiosis), rather than the presence of pathogens, is suffi-
cient for the development of joint disease [3–5]. Others
and we have reported on an analogous dysbiotic process
in the intestinal and oral microbiome of RA and psoriatic
arthritis (PsA) patients [6–8].
The lung has also been implicated as a potential site of
extra-articular autoimmune generation [9]. This is based
on the epidemiological association between tobacco
smoking and RA, the finding of distal airway lesions in
early disease and at-risk individuals, and the presence of
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ACPAs in induced sputum of RA patients (even in the
absence of circulating autoantibodies) and lung tissue
[10–13]. Enrichment of the lower airway microbiome
with taxa commonly found in the upper airways is asso-
ciated with local markers of ongoing inflammation [14,
15]. However, the potential contribution of the lung
microbiome in early disease has never been investigated.
Here, we performed research bronchoscopies to
characterize the microbiota composition in the bronch-
oalvolar lavage (BAL) of early-untreated RA to compare
it with that of a well-defined inflammatory lung disease
(sarcoidosis) and to relate it to local and systemic im-
mune response.
Methods
Patients
Patients diagnosed with RA according to 1987 ACR cri-
teria [16] and included in the LUng investigation in early
RA (LURA) study at Karolinska University Hospital in
Stockholm [13] underwent research bronchoscopy, with
retrieval of BAL as described in previous studies [11].
Newly diagnosed pulmonary sarcoidosis patients and
healthy volunteers were enrolled as controls. In parallel,
newly diagnosed sarcoidosis patients and healthy volun-
teers were enrolled as controls by the same investigators
as those performing bronchoscopy on RA patients (SK,
MS, and AE). All subjects were enrolled at the Karo-
linska University Hospital in Stockholm.
Detailed demographic characteristics of the patients
are given in Table 1. None of the participants reported
recent antibiotic usage (<3 months).
RA patients had symptom duration of less than a year
(median 6 months, range 3–12 months) and a median
age of 59 years (range 28–76 years). None of them have
ever received any oral glucocorticoids, disease-modifying
anti-rheumatic drugs (DMARDs), or biologic drugs. All
included RA patients had imaging of the thorax. Paren-
chymal changes were defined as the presence of nodules
larger than 3 mm, ground-glass opacities, opacities, fi-
brosis, and emphysema. Twelve out of 20 RA patients
had at least one of these abnormalities on CT double
blind evaluation.
All sarcoidosis patients had typical clinical signs and
symptoms of sarcoidosis (including cough, fever, chest
pain, and fatigue) and chest X-ray findings compatible
with sarcoidosis. Diagnosis was set according to criteria
established by WASOG guidelines, with biopsies show-
ing non-caseating granuloma formation and/or through
differential BALF cell counts showing an elevated BALF
CD4/CD8 ratio (median 5.7; min-max 1.3–24.9), and by
ruling out other causes of these observations. In six of
the patients, CT scans were also performed in addition
to chest radiography.
Patients with Löfgren’s syndrome were identified by
acute onset of the disease with fever, erythema nodosum,
and/or ankle arthritis, and bilateral hilar adenopathy
with or without concomitant parenchymal infiltrates.
Chest radiographic classification of patients with sar-
coidosis showed that four had stage I (hilar lymphaden-
opathy), four were in stage II (pulmonary infiltrates with
hilar lymphadenopathy), and two patients were in stage
III (pulmonary infiltrates without hilar lymphadenop-
athy). All patients with Löfgren’s syndrome had chest
radiographic stage I or II. None of the sarcoidosis pa-
tients had received any immunosuppressant therapy at
the time of bronchoscopy.
Healthy controls, with a normal chest X-ray and a me-
dian age of 28 years (range 19–50), were concomitantly
recruited through advertisement at the Lung Allergy
Clinic, Karolinska University Hospital, Solna, Sweden.
Bronchoscopies and lavage were done in a similar fash-
ion as in RA and sarcoidosis patients. None of the
healthy controls had clinically relevant airway infections
or allergy symptoms at the time of bronchoscopy, and
subjects diagnosed with asthma, COPD, other lung dis-
eases, or other inflammatory conditions were excluded
from the study. Written informed consent was obtained
from all subjects, and the Regional Ethical Review Board
in Stockholm approved the studies.
Procedures
Bronchoscopy was performed as previously described
[17, 18]. Whole unfractionated BAL samples were uti-
lized for 16S sequencing analysis (see Additional file 1
for more details).
Antibody assays
Anti-CCP2 antibodies in the serum and BAL were de-
tected using the enzyme-linked immunosorbent assay
(ELISA) (Euro-Diagnostica AB, Sweden) according to
manufacturer’s instructions. Serum samples were ana-
lyzed for specific ACPA IgGs using a custom-made pep-
tide microarray based on the ImmunoCAP ISAC system
(PhaDia) described in detail earlier [19].
Statistical analysis
In order to identify differentially abundant bacterial taxa
among the three groups, we applied the Benjamini and
Hochberg false discovery rate (FDR) test and/or the
LefSe analytic method. For cross-sectional analyses of
baseline characteristics and comparison of diversity in-
dexes between groups, differences were evaluated using
the two-tailed Student’s t test. The ANOSIM test was
applied to the unweighted UniFrac distance matrix con-
taining all analyzed samples in order to define if the
overall structure of the microbiota was significantly dif-
ferent between the different groups. P values less than
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0.05 were considered significant. Spearman’s correlation
analyses were used to assess potentially clinically rele-
vant associations on all taxa, irrespective of statistical
threshold. The optimal Bayesian network structure was
inferred through the “high climbing” algorithm imple-
mented in the bnlearn R package (see Additional file 1
for more details and references).
Results
Patients
Detailed demographic characteristics of the patients and
controls used in the study are given in Table 1. Compared
to healthy and sarcoidosis patients, RA subjects were
significantly older. Eighty percent of the RA patients were
ACPA positive. In the spirometry test, sarcoid patients
had significantly lower volume capacity (VC), forced vital
capacity (FVC), and forced expiratory volume in 1 s
(FEV1) compared to RA and healthy individuals. When
comparing the BAL fluid content, the pulmonary sarcoid-
osis patients had significantly higher proportion of
lymphocytes and hence lower proportion of macrophages,
compared to RA and healthy.
Distinct features of the lower airway microbiota
All BAL samples yielded 16S rRNA V4 gene sequences
with a median depth of sequencing of 6365 reads per
sample (IQR = 5,397–8061). When compared to healthy
subjects, BAL microbial alpha-diversity was significantly
Table 1 Clinical and Demographic characteristics of participants
Rheumatoid arthritis Sarcoidosis Healthy controls P value
Number of subjects, n 20 10 28
Female, n (%) 8 (40 %) 3 (30 %) 14 (50 %) 0.52
Age (years), median (range) 59 (28–76) 40 (30–63) 28 (19–50) <0.001
ACPA positive, n (%) 16 (80 %) 0 (0%) 1b (4 %) <0.001
Smoking 0.005
Non-smokers, n (%) 4 (20 %) 4 (40 %) 14 (50 %)
Ex-smokers, n (%) 7 (35 %) 4 (40 %) 0 (0 %)
Current-smokers, n (%) 9 (45 %) 2 (20 %) 14 (50 %)
Disease activity
DAS28, median (range) 4.42 (2.97–6.69) n.a. n.a. n.a.
CRP, median (range) 10.5 (1–54) n.a. n.a. n.a.
ESR, median (range) 20 (4–77) n.a. n.a. n.a.
Bone erosion, n (%) 7 (35 %) n.a. n.a. n.a.
Löfgren syndrome, n (%) n.a. 5 (50 %) n.a. n.a.
Pulmonary function test
VC (%), median (range) 104 (74–136) 85.5 (64–93)c n.a. 0.002
FVC (%), median (range) 106 (77–138) 86 (66–90)d 107 (84–135) 0.004
FEV1 (%), median (range) 96 (49–126) 76.5 (64–95)
c 103 (82–122) 0.006
DLCO (%), median (range) 80 (40–135) 75 (66–84)
d n.a. 0.43
Bronchoscopy
BAL recovery (%), median (range) 58 (30–85) 68 (45–76) 69 (25–80) 0.07
BAL cell concentration (106 cells L−1), median (range) 160.5 (78.7–710) 172.75 (80–388) 153.25 (14.3–987.2) 0.90
Macrophages (%), median (range) 91.4 (56.4–97.4) 69.9 (46.6–94.8) 93.8 (71.8–99)a <0.001
Lymphocytes (%), median (range) 7.2 (2–34) 27.6 (4.2–49.3) 4.2 (0.4–14.8)a <0.001
Neutrophils (%), median (range) 1.5 (0.2–7) 1.6 (0.5–4) 0.6 (0.2–18.8)a 0.05
Eosinophils (%), median (range) 0 (0–5) 0.1 (0–3.7) 0.2 (0–0.8)a 0.21
Between groups comparisons were made with one-way ANOVA (normally distributed continuous variables), the Kruskal-Wallis test (non-normally distributed
continuous variables), and the χ2 test (categorical variables)
Pulmonary function test (values show % of predicted): VC vital capacity, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCO diffusing capacity of
the lung for CO
BAL bronchoalveolar lavage
a1 missing data
b3 missing data
c4 missing data
d5 missing data
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reduced in both RA and sarcoidosis samples, as calcu-
lated by the total number of operational taxonomic units
(OTUs) present, the Simpson diversity index, and the
Faith’s phylodiversity index (Fig. 1a–c). Subsequently, we
analyzed whether the overall structure of the microbiota
of healthy samples differed from that of RA and sarcoid-
osis based on unweighted UniFrac distance. We further
applied PCoA to cluster samples along orthogonal axes
of maximal variance. As shown in Fig. 1d, β-diversity
plots differentiated the lung microbiota of healthy individ-
uals, as compared to RA or sarcoidosis patients (ANOSIM
test; P = 0.002 and 0.021 for healthy vs RA and healthy vs
sarcoidosis, respectively). However, no significant differ-
ences were found in β-diversity between RA and sarcoid-
osis patients. Further, β-diversity analysis did not
differentiate smokers from non-smokers (P = n.s.; data not
shown). Comparison of unweighted UniFrac distances be-
tween pairs of samples between different groups showed
that the microbial community structure in RA and
sarcoidosis patients was more closely related to each other
than to healthy subjects (Additional file 2: Figure S1).
RA and sarcoidosis BAL lack several taxa found in healthy
individuals
To further investigate which bacterial taxa were distinct
among groups, we first analyzed the relative abundance of
the most abundant taxa. As shown in Fig. 2, a heatmap re-
vealed that most samples contained taxa belonging to the
genera Prevotella and Streptococcus, and a genus anno-
tated within the Xanthomonadaceae family. Other taxa
(such as Paraprevotellaceae, Chryseobacterium, and Bur-
khordelia), while commonly found in healthy BAL, were
less frequently present in samples from RA and sarcoid
patients. We then applied Kruskall-Wallis followed by
FDR correction and LefSe analysis (see Additional file 1)
to better characterize these findings. Noticeably, the
Fig. 1 BAL microbiota richness and diversity. Alpha diversity was calculated using number of OTUs (a), Simpson diversity index (b), and the Faith’s
phylodiversity index (c), all revealing significant differences between healthy subjects and sarcoid or RA. No significant differences were found
between both patient groups. Beta diversity (d) demonstrated that RA and sarcoid samples clustered together and away from healthy controls.
**P < 0.01; ***P < 0.001; ****P < 0.0001; ns non-significant
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relative abundance of several microbial clades was de-
creased in RA and sarcoidosis samples compared to
healthy controls (Fig. 3). Within these identified taxa,
RA BAL samples had a decrease in the families
Burkholderiaceae, Actinomycetaceae, and Spirochaeta-
ceae. In fact, 68 % of the healthy control BAL contained
Actinomycetaceae and 36 % had Spirochaetaceae, com-
pared to 5 and 0 % in RA BAL, respectively (Fig. 3; P <
0.0001 for Actinomycetaceae and P = 0.0009 for Spiro-
chaetaceae). At the genus level of taxonomic classifica-
tion, Burkholderia was significantly decreased in both
RA and sarcoidosis compared to controls, although there
was no difference between disease groups (Fig. 3b).
Contrary to our initial hypothesis that we would find a
proportion of RA patients’ BAL containing Porphyromo-
nas (potentially as a consequence of microaspiration of
this periodontopathic genus), only 10 % of these samples
contained sequences belonging to the genus. Curiously,
however, 40% of the healthy controls BAL showed the
presence of Porphyromonas (LDA score >3 vs RA and sar-
coidosis; not achieving FDR; Additional file 3: Figure S2A,
B). Similarly, the genus Treponema (also highly associated
with periodontitis) was exclusively found in healthy sub-
jects’ BAL (P < 0.01 vs RA; Fig. 3c and Additional file 3:
Figure S2A). Comparable taxonomic differences were
found between sarcoid and healthy BAL, with only a few
genera being characteristic of sarcoid samples (Additional
file 3: Figure S2B, C).
The use of state-of-the-art high-throughput sequencing
platform allowed us for an in-depth analysis of the micro-
biota, including the characterization of the BAL OTUs
that differentiate between groups. Several OTUs had a
decreased relative abundance in RA BAL compared to
healthy controls, including two belonging to the genus
Actinomyces, one to Burkhodelia and another one to
Prevotella (Fig. 3). Intriguingly, several of these OTUs
were also decreased in sarcoidosis BAL, suggesting a po-
tential common “inflammatory” lung microbiota signature
for both conditions (Fig. 3; P = ns sarcoidosis vs RA).
Although not achieving FDR, a few genus such as Methy-
lobacterium, Micrococcus, and Pseudonocardia were more
abundant in RA BAL compared to healthy controls
(LDA > 3 vs healthy, Additional file 3: Figure S2). More-
over, an OTU aligned to Pseudonocardia (6305560) was
the only BAL OTU overrepresented in the RA group
when compared to both healthy controls and sarcoidosis
patients (P < 0.01 and P < 0.05, respectively; although not
achieving FDR; Additional file 4: Figure S3A).
Local lung and systemic autoimmune generation in
untreated, early RA is associated with characteristic BAL taxa
To further investigate whether the observed alterations
in BAL bacterial community composition in early RA
patients was associated with phenotypic characteristics
or metadata, we set out to describe the correlations
between the relative abundance of taxa and (1) clinical
disease activity (DAS28-ESR and CRP), (2) the local
autoimmune response (BAL concentrations of ACPA
and percentage of immune cells), and (3) the systemic
immune response (serum concentrations of ACPA and
RF) (Fig. 4 for genus; and Additional file 5: Figure S4 for
OTUs). An optimal Bayesian network, which incorpo-
rates correlations between taxa, was also performed [see
Additional file 6: Figures S5 (genus) and 6 (OTUs)].
This analysis revealed that RA disease activity was
positively correlated with Micrococcus and Renibaterium
Fig. 2 Taxonomic heatmap for each group. Characteristic relative abundance of various genus in healthy subjects (in blue), sarcoid (in green), and
RA patients (in red). Each column represents a unique subject. On the far right are the most abundant genus found (mean > 0.5%) for all groups
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at the genus level, and with various OTUs belonging to
Pseudonocardia, Streptococcus, and Xanthomonadaceae
(Fig. 4 and Additional file 5: Figure S4). The level of
BAL eosinophils was also correlated with clinical activity
(Additional file 6: Figure S5). Conversely, an unclassified
Oxalobacteraceae genus had a negative correlation with
DAS28 score at the time of BAL sampling (Fig. 4). A
modest association with erosive disease was observed
with the presence and abundance of Pseudonocardia in
the RA BAL (85% of erosive RA patients vs 23% of non-
erosive RA; P = 0.019 Additional file 4: Figure S3B).
Noticeably, levels of BAL autoantibodies (i.e., anti-CCP2
in the BAL) correlated positively with the genus Mega-
sphera and unclassified Comamonadaceae (Fig. 4) as
well as OTUs belonging to these taxa (Additional file 5:
Figure S4).
Serum IgA anti-CCP antibodies had a positive signifi-
cant correlation with relative abundance of BAL Enhy-
drobacter and unclassified Bradyrhizobiaceae (Fig. 4; P =
0.015 and 0.004, respectively) and also with OTUs
related to these and other genera, including Veillonella
and unclassified Stramenopiles (Additional file 5: Figure
S4). Serum IgG anti-CCP2 antibodies associated with an
OTU related to unclassified Comamonadaceae within
the RA BAL. The number of ACPA fine specificities in
serum (NEFS) showed a positive correlation only with
the genus Prevotella (Fig. 4) and with OTUs related to
Stramenopiles and Streptococcus (Additional file 5:
Figure S4 and Additional file 7: Figure S6).
Finally, while neutrophil abundance in BAL positively
correlated with the genus Neisseria and a related OTU,
lymphocytes levels were associated with the genus TM-7
and OTUs belonging to the genus Prevotella.
Discussion
The role of the lung microbiome as mediator of inflam-
mation has only recently emerged. Novel relevant work
in the field revealed that (a) the human distal airways
harbor several bacterial species constituting a unique
ecological community [14, 20–26] and (b) changes upon
alveolar inflammation occur in the presence of a dis-
tinctive microbial pneumotype [14, 15]. Utilizing high-
throughput 16S sequencing we show here, for the first
time, that the lung microbial composition in patients
with early-untreated RA and lung sarcoidosis have a
high degree of similarity and are significantly different
from those of healthy controls. Importantly, several mi-
crobial signatures were associated with the inflammatory
Fig. 3 Relative abundance at the family, genus, and OTU levels. RA BAL samples showed a significant decrease in Actynomyces (and related
OTUs), Burkholderia (and related OTUs), and Treponema (and Prevotella-related OTU), compared to healthy controls. A similar trend for Burkholderia
and the family Spirochaetaceae was observed for sarcoid BAL. The relative abundance (and presence) of the genus Porphyromonas in healthy BAL
was also higher than in RA and sarcoid samples. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns non-significant
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phenotype observed in RA. These findings further sup-
port the hypothesis that changes occurring in the lung
microbial/host interface might contribute to disease
pathogenesis in early stages of RA development.
In fact, the overall lung bacterial community structure
in RA patients harbors 40 % less OTUs than healthy in-
dividuals. This is in line with prior studies in early RA
subjects reporting dysbiotic states at other mucosal sites
[7, 8, 27]. Interestingly, this decreased taxa diversity is
very similar to what we found in BAL samples of
sarcoidosis patients (a well-characterized inflammatory
disease of the lung parenchyma). Importantly, RA and
sarcoidosis patients not only shared an overall decreased
BAL microbial richness and diversity, but the taxa driving
the dysbiotic process were remarkably similar. Indeed,
most higher taxonomic clades that were underrepresented
in RA BAL compared to healthy subjects were also dimin-
ished or absent in sarcoidosis samples, including the
families Burkholderiaceae, Actinomycetaceae, and Spiro-
chaetaceae and the genera Actynomyces, Treponema, and
Porphyromonas. The high degree of similarity between the
lung microbiome in RA and sarcoidosis, despite the fact
that RA patients were more frequently smokers and
significantly older, suggests the possibility that airway
mucosal inflammation is a potential driver of lung dysbio-
sis independently of smoking and age in both diseases.
Alternatively, it is conceivable that the inflammatory
process present in both disease states might also have an
impact on the lung microbiota community. Importantly,
however, RA patients were enrolled early in the disease
process, therefore minimizing the confounding effects of
prolonged inflammatory states and/or immunomodula-
tory therapeutic consequences on the microbiome [24].
Despite these similarities between RA and sarcoidosis,
few exceptions exist. Pseudonocardia, most notably, was
one of the few genera found to be more abundant in RA
BAL compared to healthy controls and also the one cor-
relating with higher disease activity (OTU level) and
erosive arthritis. Pseudonocardia is a known antifungal
commensal microorganism [28] and a higher abundance
of this taxon might rather reflect the presence of fungal
organisms in the distal airways. Although fungi have
been implicated in the pathogenesis of the SKG arthritis
model [29], we did not assess for their presence in the
current study. Efforts are underway to incorporate
mycobiome analysis into our current and future studies.
Interestingly, the presence of the genus Prevotella in
the RA BAL (and a Prevotella-related OTU) significantly
Fig. 4 RA BAL microbiota correlations with local/systemic autoimmunity, inflammatory markers, and clinical disease activity. The relative
abundance of BAL taxa (genus level) was assessed for correlations with disease activity score (DAS28), the levels of serum acute phase reactants and
autoantibodies (including number of fine specificities), and BAL levels of anti-CCP2 and immune cells (%). The heat map shows the correlations
between patient metadata and BAL microbiota at the genus level. Circle sizes and color intensity represent the magnitude of correlation. Blue
circles = positive correlations; red circles = negative correlations. CRP C-reactive protein, NEFS number of ELISA ACPA fine specificities
Scher et al. Microbiome  (2016) 4:60 Page 7 of 10
correlated with levels of systemic RF (IgA) and the num-
ber of ACPA fine specificities. This is in line with previ-
ous studies describing the presence of this genus in the
RA-associated oral mucosa and showing that Prevotella
nigrescens can trigger arthritis in mice [30, 31]. However,
despite previous speculations regarding the arthritogenic
potential of other periodontopathic microorganisms
(most notably P. gingivalis), we report here a general
underrepresentation of several of these genera in the
BAL, including not only Actinomyces and Prevotella but
Porphyromonas as well. P. gingivalis, one of the Porphyr-
omonas species, carries the enzyme petydil-arginine-
deiminase (PAD), which is responsible for the transla-
tional modification of arginine residues into citrullinated
peptides, ultimately leading to the generation of neo-
epitopes recognized by ACPAs [27, 30, 32–34]. Although
our a priori hypothesis was that we would find higher
prevalence of P. ginigvalis in the BAL, presumably via
microaspiration, the seemingly paradoxical lower relative
abundance of Porphyromonaceae phylum compared to
controls aligns with recent studies concluding that mu-
cosal periodontal inflammation (but not P. gingivalis
abundance per se) is associated with RA prevalence [33].
Whether this represents a true lack of association or a
site-specific lack of correlation remains to be further
elucidated.
Our results also confirm previous data showing that the
distal airway compartment is not sterile and provide de-
tailed characterization of the local bacterial taxa using
high-throughput sequencing. Although the material stud-
ied here is a unique one (consisting of BAL of early-
untreated RA patients with short symptom duration and
no clinical signs of lung involvement), the relatively low
number of participants is a limitation. Bronchoscopic
sampling was restricted to only one site in the lower air-
ways, thus regional variation could not be investigated.
Additionally, no oral samples were concomitantly ob-
tained, so the question of cross-contamination with oral
secretions could not be evaluated. However, contamin-
ation with oropharyngeal microbiota, once a matter of
great debate, has not been shown to be a major and fre-
quent event that would preclude utilization of bronchos-
copy to sample the lower airways [14, 15, 23, 35]. Further,
although technical controls were included in our se-
quence, BAL samples were obtained prior to adapting
our now standardized protocol that uses broncho-
scopic environmental controls. This controls may also
be of relevance for microbiome studies with low bio-
mass samples [36, 37]. Although healthy subjects were
significantly younger, age has not been found to be a
major factor in other lung microbiome studies [14,
22, 26]. However, it is conceivable that an age-related
decrease in bacterial clearance and/or a relatively less
robust immune response to the antigenic load could
potentially alter the composition of the lower airway
microbiome. Finally, our study does not address whether
these dysbiotic changes precede or are rather a conse-
quence of the inflammatory process. Studies on preclinical
disease state, although difficult to perform given the
cohort characteristics and the invasiveness of bronchos-
copy, will be required to address this issue.
Conclusions
In summary, we demonstrate that RA is characterized
by a state of distal airway dysbiosis similar to that seen
in sarcoidosis, a well-characterized inflammatory lung
disease. We further identify a lower relative abundance
of several taxa and a concomitant disease specific over-
representation of a Pseudonocardia OTU in RA. Future
mechanistic insights into directionality and possible
causation will most likely be dependent on well-
characterized prospective human studies and data
derived from in vivo experiments from animal models.
Additional files
Additional file 1: Supplemental materials (DOCX 39 kb)
Additional file 2: Figure S1. Unweighted UniFrac distance metric was
used to compare BAL microbial communities within and between
groups. Healthy BAL community structure was significantly different from
sarcoid (A) and RA (B). By contrast, sarcoidosis and RA groups revealed a
closer relative relatedness of taxonomic composition (C). (JPEG 146 kb)
Additional file 3: Figure S2. Cladrogram showing significantly different
BAL genus by LefSe. (A) RA vs healthy, (B) sarcoid vs healthy, and (C) RA
vs sarcoid. Empty bars reflect LDA effect size for each genera. Colored
bars show taxa relative abundance for indicated groups. (JPEG 527 kb)
Additional file 4: Figure S3. Relative abundance of Pseudonocardia
OTU in RA vs healthy and sarcoidosis (A) and correlation between genus
Pseudonocardia and erosive RA (B). (JPEG 91 kb)
Additional file 5: Figure S4. RA BAL operational taxonomic unit (OTU)
correlations with local/systemic autoimmunity, inflammatory markers and
clinical disease activity. The relative abundance of BAL taxa was assessed for
correlations with disease activity score (DAS28), the levels of serum acute
phase reactants and autoantibodies (including number of fine specificities),
and BAL levels of anti-CCP2 and immune cells (%). The heat map shows the
correlations between patient metadata and BAL microbiota at the
OTU level. Circle sizes and color intensity represent the magnitude of
correlation. Blue circles = positive correlations; red circles = negative
correlations. CRP = C-reactive protein; ESR = erythrosedimentation rate;
NFS = number of ACPA fine specificities (ISAC chip); NEFS = number
of ELISA ACPA fine specificities (JPEG 232 kb)
Additional file 6: Figure S5. Optimal Bayesian network analysis at the
genus level. Green circles = taxa; blue circles = metadata; black lines =
positive correlations; blue lines = negative correlations. (JPEG 149 kb)
Additional file 7: Figure S6. Optimal Bayesian network analysis at the
OTU level. Green circles = taxa; blue circles = metadata; black lines =
positive correlations; blue lines = negative correlations. (JPEG 173 kb)
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